Drug Type Small molecule drug |
Synonyms Dofequidar, MS-209 |
Target |
Action inhibitors |
Mechanism P-gp inhibitors(P-glycoprotein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC34H35N3O7 |
InChIKeyQIAVTDQTRFYXSD-WLHGVMLRSA-N |
CAS Registry153653-30-6 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Phase 3 | Japan | - | - |
| Breast Cancer | Phase 3 | - | - | |
| Non-Small Cell Lung Cancer | Phase 3 | Japan | - | - |
| Non-Small Cell Lung Cancer | Phase 3 | - | - | |
| Neoplasms | Phase 2 | United States | - | - |
| Neoplasms | Phase 2 | Europe | - | - |
| Advanced Malignant Solid Neoplasm | Phase 1 | France | 01 Dec 1999 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | Germany | 01 Dec 1999 |





